Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
3.
J Hosp Infect ; 108: 33-42, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33152397

ABSTRACT

BACKGROUND: Understanding the transmission and dispersal of influenza virus and respiratory syncytial virus (RSV) via aerosols is essential for the development of preventative measures in hospital environments and healthcare facilities. METHODS: During the 2017-2018 influenza season, patients with confirmed influenza or RSV infections were enrolled. Room air samples were collected close (0.30 m) to and distant (2.20 m) from patients' heads. Real-time polymerase chain reaction was used to detect and quantify viral particles in the air samples. The plaque assay was used to determine the infectiousness of the detected viruses. FINDINGS: Fifty-one air samples were collected from the rooms of 29 patients with laboratory-confirmed influenza; 51% of the samples tested positive for influenza A virus (IAV). Among the IAV-positive patients, 65% were emitters (had at least one positive air sample), reflecting a higher risk of nosocomial transmission compared with non-emitters. The majority (61.5%) of the IAV-positive air samples were collected 0.3 m from a patient's head, while the remaining IAV-positive air samples were collected 2.2 m from a patient's head. The positivity rate of IAV in air samples was influenced by distance from the patient's head and day of sample collection after hospital admission. Only three patients with RSV infection were recruited and none of them were emitters. CONCLUSION: Influenza virus can be aerosolized beyond 1 m in patient rooms, which is the distance considered to be safe by infection control practices. Further investigations are needed to determine the extent of infectivity of aerosolized virus particles.


Subject(s)
Air Microbiology , Influenza A virus/isolation & purification , Patients' Rooms , Respiratory Syncytial Virus, Human/isolation & purification , Adolescent , Adult , Aged , Child , Child, Preschool , Cross Infection/prevention & control , Female , Humans , Infant , Infant, Newborn , Influenza, Human , Male , Middle Aged , Respiratory Syncytial Virus Infections , Young Adult
4.
Clin Microbiol Infect ; 23(8): 544-549, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28159672

ABSTRACT

OBJECTIVES: Left-sided methicillin-susceptible Staphylococcus aureus (MSSA) endocarditis treated with cloxacillin has a poorer prognosis when the vancomycin minimum inhibitory concentration (MIC) is ≥1.5 mg/L. We aimed to validate this using the International Collaboration on Endocarditis cohort and to analyse whether specific genetic characteristics were associated with a high vancomycin MIC (≥1.5 mg/L) phenotype. METHODS: All patients with left-sided MSSA infective endocarditis treated with antistaphylococcal ß-lactam antibiotics between 2000 and 2006 with available isolates were included. Vancomycin MIC was determined by Etest as either high (≥1.5 mg/L) or low (<1.5 mg/L). Isolates underwent spa typing to infer clonal complexes and multiplex PCR for identifying virulence genes. Univariate analysis was performed to evaluate the association between in-hospital and 1-year mortality, and vancomycin MIC phenotype. RESULTS: Sixty-two cases met the inclusion criteria. Vancomycin MIC was low in 28 cases (45%) and high in 34 cases (55%). No significant differences in patient demographic data or characteristics of infection were observed between patients with infective endocarditis due to high and low vancomycin MIC isolates. Isolates with high and low vancomycin MIC had similar distributions of virulence genes and clonal lineages. In-hospital and 1-year mortality did not differ significantly between the two groups (32% (9/28) vs. 27% (9/34), p 0.780; and 43% (12/28) vs. 29% (10/34), p 0.298, for low and high vancomycin MIC respectively). CONCLUSIONS: In this international cohort of patients with left-sided MSSA endocarditis treated with antistaphylococcal ß-lactams, vancomycin MIC phenotype was not associated with patient demographics, clinical outcome or virulence gene repertoire.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Vancomycin/pharmacology , beta-Lactams/therapeutic use , Adult , Aged , Aged, 80 and over , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/mortality , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Molecular Typing , Multiplex Polymerase Chain Reaction , Prospective Studies , Staphylococcal Infections/microbiology , Staphylococcus aureus/classification , Staphylococcus aureus/genetics , Staphylococcus aureus/isolation & purification , Survival Analysis , Treatment Outcome , Virulence Factors/genetics
5.
Antimicrob Agents Chemother ; 60(10): 6341-9, 2016 10.
Article in English | MEDLINE | ID: mdl-27527083

ABSTRACT

The phenotypic expression of methicillin resistance among coagulase-negative staphylococci (CoNS) is heterogeneous regardless of the presence of the mecA gene. The potential discordance between phenotypic and genotypic results has led to the use of vancomycin for the treatment of CoNS infective endocarditis (IE) regardless of methicillin MIC values. In this study, we assessed the outcome of methicillin-susceptible CoNS IE among patients treated with antistaphylococcal ß-lactams (ASB) versus vancomycin (VAN) in a multicenter cohort study based on data from the International Collaboration on Endocarditis (ICE) Prospective Cohort Study (PCS) and the ICE-Plus databases. The ICE-PCS database contains prospective data on 5,568 patients with IE collected between 2000 and 2006, while the ICE-Plus database contains prospective data on 2,019 patients with IE collected between 2008 and 2012. The primary endpoint was in-hospital mortality. Secondary endpoints were 6-month mortality and survival time. Of the 7,587 patients in the two databases, there were 280 patients with methicillin-susceptible CoNS IE. Detailed treatment and outcome data were available for 180 patients. Eighty-eight patients received ASB, while 36 were treated with VAN. In-hospital mortality (19.3% versus 11.1%; P = 0.27), 6-month mortality (31.6% versus 25.9%; P = 0.58), and survival time after discharge (P = 0.26) did not significantly differ between the two cohorts. Cox regression analysis did not show any significant association between ASB use and the survival time (hazard ratio, 1.7; P = 0.22); this result was not affected by adjustment for confounders. This study provides no evidence for a difference in outcome with the use of VAN versus ASB for methicillin-susceptible CoNS IE.


Subject(s)
Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus/pathogenicity , Vancomycin/therapeutic use , beta-Lactams/therapeutic use , Aged , Coagulase/metabolism , Cohort Studies , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/mortality , Female , Hospital Mortality , Humans , Male , Methicillin/pharmacology , Middle Aged , Prospective Studies , Staphylococcal Infections/microbiology , Staphylococcal Infections/mortality , Staphylococcus/drug effects , Staphylococcus/metabolism
6.
Int J Antimicrob Agents ; 41(1): 75-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23142087

ABSTRACT

A recent increase in carbapenem resistance among extended-spectrum ß-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates at a major tertiary care centre in Lebanon prompted the initiation of this study. Consecutive ESBL-producing isolates were tested for resistance to carbapenems, with initial screening by disk diffusion and Etest using ertapenem. The modified Hodge test was also performed. PCR of ß-lactamase-encoding genes, including bla(NDM-1), bla(KPC), bla(OXA-48), bla(CTX-M), bla(TEM), bla(SHV), bla(CMY-2) and bla(OXA-1), as well as outer membrane porin genes (ompC and ompF) was performed. Sequencing, efflux pump inhibitor tests and random amplified polymorphic DNA (RAPD) analysis were performed. In total, 14 (2.45%) of 572 K. pneumoniae and 24 (1.07%) of 2243 E. coli were ertapenem-non-susceptible [minimum inhibitory concentration (MIC) ≥0.25 µg/mL]. Resistance to other carbapenems was variable. PCR and sequencing analysis revealed that isolates harboured different ß-lactamase genes, including bla(OXA-1), bla(CTX-M-15), bla(TEM-1), bla(CMY-2), bla(OXA-48) and bla(NDM-1). In addition, K. pneumoniae lacked the outer membrane porin-encoding genes, whilst E. coli harboured them with detected mutations. CTX-M-15 was carried on a 90 kb plasmid, whilst OXA-48 was carried on a 70 kb plasmid. Efflux pump inhibition significantly decreased MICs in E. coli. RAPD analysis demonstrated genomic variability. In conclusion, carbapenem resistance in ESBL-producing K. pneumoniae and E. coli is due to the combined effect of ß-lactamases with porin impermeability and/or efflux pump activity observed in these organisms, and in a number of isolates is due to the production of the carbapenemase-encoding genes bla(OXA-48) and the newly emerging bla(NDM-1).


Subject(s)
Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , beta-Lactam Resistance , beta-Lactamases/genetics , Enterobacteriaceae Infections/microbiology , Escherichia coli/genetics , Escherichia coli/isolation & purification , Humans , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/isolation & purification , Lebanon , Microbial Sensitivity Tests , Plasmids , Random Amplified Polymorphic DNA Technique , Sequence Analysis, DNA , Tertiary Care Centers , beta-Lactamases/metabolism
7.
J Infect Public Health ; 3(1): 5-16, 2010.
Article in English | MEDLINE | ID: mdl-20701886

ABSTRACT

Although uncommon, spontaneous and postoperative pyogenic spondylodiscitis entail major morbidity and may be associated with serious long-term sequelae. A review of the literature was done to advance our understanding of the diagnosis, treatment, and outcome of these infections. The principles of conservative treatment are to establish an accurate microbiological diagnosis, treat with appropriate antibiotics, immobilize the spine, and closely monitor for spinal instability and neurological deterioration. The purpose of surgical treatment is to obtain multiple intraoperative cultures of bone and soft tissue, perform a thorough debridement of infected tissue and decompression of neural structures, and reconstruct the unstable spinal column with bone graft with or without concomitant instrumentation. Appropriate management requires aggressive medical treatment and, at times, surgical interventions. If recognized early and treated appropriately, a full recovery can often be expected. Therefore, clinicians should be aware of the clinical presentation of such infections to improve patient outcome.


Subject(s)
Back Pain/etiology , Bacterial Infections/diagnosis , Discitis/microbiology , Spine/surgery , Anti-Infective Agents/therapeutic use , Back Pain/microbiology , Back Pain/therapy , Bacterial Infections/drug therapy , Debridement , Decompression, Surgical , Diagnosis, Differential , Discitis/diagnosis , Discitis/therapy , Humans , Postoperative Complications , Treatment Outcome
8.
Eur J Clin Microbiol Infect Dis ; 29(10): 1203-10, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20549531

ABSTRACT

Referral bias occurs because of the clustering of patients at tertiary care centers. This may result in the distortion of observed clinical manifestations of rare diseases. This analysis evaluates the effect of referral bias on the epidemiology of infective endocarditis (IE) in the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS). This is a prospective multicenter cohort study comparing transferred and non-transferred patients with IE. Factors independently associated with transfer status were evaluated using multivariable logistic regression. A total of 2,760 patients were included in the analysis, of which 1,164 (42.2%) were transferred from other medical centers. Transferred patients more often underwent surgery for IE (odds ratio [OR] = 2.5; 95% confidence interval [CI] 1.9-3.2). They were also more likely to have complications such as stroke (OR = 1.5; 95% CI 1.3-1.9), heart failure (OR = 1.4; 95% CI 1.1-1.6), and new valvular regurgitation (OR = 1.3; 95% CI 1.1-1.6). The in-hospital mortality rates were similar in both groups. Patients with IE who require surgery and suffer complications are referred to tertiary hospitals more frequently than patients with an uncomplicated course. Hospital transfer has no obvious effect on the in-hospital mortality. Referral bias should be taken into consideration when describing the clinical spectrum of IE.


Subject(s)
Endocarditis/diagnosis , Endocarditis/epidemiology , Hospitalization/statistics & numerical data , Referral and Consultation/statistics & numerical data , Adult , Aged , Cohort Studies , Endocarditis/mortality , Endocarditis/pathology , Female , Humans , Male , Middle Aged , Prospective Studies
9.
Eur J Clin Microbiol Infect Dis ; 28(12): 1477-82, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19730900

ABSTRACT

The complications from S. aureus bacteremia (SAB) and infective endocarditis (SAIE) are higher in patients with diabetes. We summarize the characteristics and outcome of diabetic patients enrolled in a multicenter trial of daptomycin vs. standard therapy for SAB and SAIE. Adult patients with SAB were randomized to daptomycin 6 mg/kg/day or standard therapy (vancomycin 1 g every 12 h or antistaphylococcal penicillin 2 g every 4 h, both with gentamicin 1 mg/kg every 8 h for 4 days). Clinical success was defined as survival, resolution of S. aureus infection, and clinical outcome of cure or improved 6 weeks after end of therapy. Diabetic patients (86/235) were older, more overweight, and were more likely to present with systemic inflammatory response syndrome (SIRS) and to have complicated SAB. Clinical success rates were similar (67.4% in diabetics and 70.5% in non-diabetics). The mortality rate was significantly higher among diabetic patients (22.1% vs. 11.4%, p = 0.038). In the diabetes subgroup, the clinical success and mortality rates were comparable between the daptomycin and the standard therapy arms. The presence of diabetes is associated with significantly higher mortality in patients with SAB and SAIE. Daptomycin is an alternative therapeutic option in diabetic patients with these serious staphylococcal infections.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Diabetes Complications , Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus aureus/isolation & purification , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Bacteremia/epidemiology , Bacteremia/mortality , Daptomycin/administration & dosage , Daptomycin/therapeutic use , Endocarditis, Bacterial/epidemiology , Endocarditis, Bacterial/mortality , Female , Gentamicins/administration & dosage , Gentamicins/therapeutic use , Humans , Male , Middle Aged , Penicillins/administration & dosage , Penicillins/therapeutic use , Prevalence , Staphylococcal Infections/mortality , Survival Analysis , Systemic Inflammatory Response Syndrome/epidemiology , Treatment Outcome , Vancomycin/administration & dosage , Vancomycin/therapeutic use
10.
Clin Microbiol Infect ; 14(5): 501-4, 2008 May.
Article in English | MEDLINE | ID: mdl-18325038

ABSTRACT

The prevalence of bla CTX-M, bla TEM and bla SHV genes among extended-spectrum beta-lactamase (ESBL)-producing clinical isolates of Escherichia coli (n = 50) and Klebsiella spp. (n = 50) from Lebanon was 96%, 57% and 67%, and 40%, 82% and 84%, respectively. Genotyping revealed that the clonal diversity was unrelated to the presence of bla genes. Sequence analysis of 16 selected isolates identified the bla CTX-M-15, bla TEM-1, bla OXA-1 and six bla SHV genes, as well as the gene encoding the quinolone-modifying enzyme AAC(6')-Ib-cr. The genes encoding CTX-M-15 and AAC(6')-Ib-cr were carried on a 90-kb plasmid of the pC15-1a or pCTX-15 type, which transferred both ESBL production and quinolone resistance from donors to transconjugants.


Subject(s)
Escherichia coli/genetics , Klebsiella/genetics , beta-Lactamases/genetics , Cross Infection/microbiology , Enterobacteriaceae Infections/microbiology , Escherichia coli/enzymology , Escherichia coli Infections/microbiology , Genotype , Humans , Klebsiella/enzymology , Lebanon
11.
Eur J Clin Microbiol Infect Dis ; 27(7): 519-29, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18283504

ABSTRACT

Candida infective endocarditis (IE) is uncommon but often fatal. Most epidemiologic data are derived from small case series or case reports. This study was conducted to explore the epidemiology, treatment patterns, and outcomes of patients with Candida IE. We compared 33 Candida IE cases to 2,716 patients with non-fungal IE in the International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS). Patients were enrolled and the data collected from June 2000 until August 2005. We noted that patients with Candida IE were more likely to have prosthetic valves (p < 0.001), short-term indwelling catheters (p < 0.0001), and have healthcare-associated infections (p < 0.001). The reasons for surgery differed between the two groups: myocardial abscess (46.7% vs. 22.2%, p = 0.026) and persistent positive blood cultures (33.3% vs. 9.9%, p = 0.003) were more common among those with Candida IE. Mortality at discharge was higher in patients with Candida IE (30.3%) when compared to non-fungal cases (17%, p = 0.046). Among Candida patients, mortality was similar in patients who received combination surgical and antifungal therapy versus antifungal therapy alone (33.3% vs. 27.8%, p = 0.26). New antifungal drugs, particularly echinocandins, were used frequently. These multi-center data suggest distinct epidemiologic features of Candida IE when compared to non-fungal cases. Indications for surgical intervention are different and mortality is increased. Newer antifungal treatment options are increasingly used. Large, multi-center studies are needed to help better define Candida IE.


Subject(s)
Candida/isolation & purification , Candidiasis/epidemiology , Candidiasis/microbiology , Endocarditis/epidemiology , Endocarditis/microbiology , Adult , Aged , Antifungal Agents/therapeutic use , Candidiasis/drug therapy , Candidiasis/mortality , Catheters, Indwelling , Cross Infection , Endocarditis/drug therapy , Endocarditis/mortality , Female , Humans , Male , Middle Aged , Prostheses and Implants , Risk Factors
12.
J Antimicrob Chemother ; 61(1): 177-82, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17999973

ABSTRACT

OBJECTIVES: To evaluate the clinical characteristics, treatment and outcomes of patients with osteoarticular infections (OAIs) associated with Staphylococcus aureus bacteraemia (SAB). METHODS: The clinical characteristics and outcomes for patients with OAI were described using a post hoc analysis of an open label, randomized trial comparing daptomycin with standard therapy (vancomycin or anti-staphylococcal penicillin with initial gentamicin) for the treatment of SAB. RESULTS: OAI occurred in 32 of 121 patients (21 daptomycin and 11 standard therapy) with complicated SAB (18 septic arthritis, 9 vertebral osteomyelitis and 7 others). Two patients had osteomyelitis in more than one site. Success rates seen in two groups were as follows: vertebral osteomyelitis [3/5 (60%) daptomycin versus 0/2 (0%) comparator], septic arthritis [7/11 (64%) versus 3/5 (60%)], sternal osteomyelitis [3/3 (100%) versus 1/2 (50%)] and long bone osteomyelitis [0/1 (0%) versus 1/1 (100%)]. Success rates in both treatment groups improved with surgical therapy. Creatine phosphokinase elevations to >500 IU/L occurred in one patient on daptomycin who discontinued therapy, whereas renal impairment developed in three patients on standard therapy, two of whom discontinued therapy. Two patients treated with daptomycin and one patient on vancomycin had increases in S. aureus MICs to daptomycin and vancomycin, respectively. Three patients treated with daptomycin died following completion of therapy, with mortality attributed to multiple co-morbid conditions and inadequate debridement of OAIs in these patients. No deaths were reported in the standard therapy group. CONCLUSIONS: Daptomycin may be considered an alternative to standard therapy in the treatment of patients with complicated SAB and OAI.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Daptomycin/therapeutic use , Osteoarthritis/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Daptomycin/administration & dosage , Drug Administration Schedule , Female , Humans , Injections, Intravenous , Male , Middle Aged , Osteoarthritis/microbiology , Staphylococcal Infections/microbiology , Staphylococcus aureus/isolation & purification , Treatment Outcome
13.
Scand J Infect Dis ; 38(6-7): 541-5, 2006.
Article in English | MEDLINE | ID: mdl-16798709

ABSTRACT

Like other non-tuberculous mycobacteria, Mycobacterium xenopi infects more commonly patients with altered immune defenses. In immunocompetent individuals, infection with M. xenopi has been described in the setting of underlying lung disease. We here report the first case of M. xenopi lung abscess in a previously healthy patient with no known predisposing factors who was successfully treated with rifampin, isoniazid and ethambutol.


Subject(s)
Lung Abscess/microbiology , Mycobacterium Infections, Nontuberculous/microbiology , Mycobacterium xenopi , Adult , Biopsy, Fine-Needle , Humans , Immunocompetence , Lung Abscess/diagnostic imaging , Lung Abscess/drug therapy , Male , Mycobacterium Infections, Nontuberculous/diagnostic imaging , Mycobacterium Infections, Nontuberculous/drug therapy , Tomography, X-Ray Computed
14.
Eur J Clin Microbiol Infect Dis ; 25(6): 365-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16767483

ABSTRACT

Infective endocarditis due to coagulase-negative staphylococci is increasingly recognized as a difficult-to-treat disease associated with poor outcome. The aim of this report is to describe the characteristics and outcome of patients with prosthetic valve endocarditis (PVE) due to coagulase-negative staphylococci versus those of patients with PVE due to Staphylococcus aureus and viridans streptococci. Patients were identified through the International Collaboration on Endocarditis Merged Database. A total of 54 cases of coagulase-negative staphylococci PVE, 58 cases of S. aureus PVE, and 63 cases of viridans-streptococci-related PVE were available for analysis. There was no difference between the three groups with respect to the type of valve involved or the rate of embolization. However, heart failure was encountered more frequently with coagulase-negative staphylococci (54%) than with either S. aureus (33%; p=0.03) or viridans streptococci (32%; p=0.02). In addition, valvular abscesses complicated 39% of infections due to coagulase-negative staphylococci compared with 22% of those due to S. aureus (p=0.06) and 6% of those due to viridans streptococci (p<0.001). Mortality was highest in patients with S. aureus and coagulase-negative staphylococcal endocarditis (47 and 36%, respectively; p=0.22) and was considerably lower in patients with viridans streptococcal endocarditis (p=0.002 compared to patients with coagulase-negative staphylococcal endocarditis). The results of this analysis demonstrate the aggressive nature of coagulase-negative staphylococcal PVE and the substantially greater morbidity and mortality associated with this infection compared to PVE caused by other pathogens.


Subject(s)
Endocarditis, Bacterial/microbiology , Heart Valve Prosthesis/microbiology , Staphylococcal Infections , Streptococcal Infections , Viridans Streptococci , Aged , Databases, Factual , Endocarditis, Bacterial/therapy , Female , Humans , Male , Middle Aged , Staphylococcal Infections/therapy , Staphylococcus/classification , Staphylococcus/enzymology , Streptococcal Infections/therapy , Treatment Outcome
15.
Parasitology ; 132(Pt 5): 635-9, 2006 May.
Article in English | MEDLINE | ID: mdl-16426480

ABSTRACT

Toxocariasis is a common helminthic infection that has a worldwide distribution. However, data from Lebanon about the prevalence of this infection are non-existent. We conducted a Toxocara seroprevalence study with 150 subjects attending the outpatient clinics at the American University of Beirut Medical Center between May and June 2004. Serum specimens were tested for anti-Toxocara antibodies by enzyme-linked immunosorbent assay and confirmed by Western blot. Multivariate analysis was performed to identify risk factors for infection. The seroprevalence rate of toxocariasis was 19%. Male gender and below high school education were significantly associated with a positive serological test (odds ratios = 3.1 and 2.8, respectively). Higher numbers of persons in the household, and low family income during childhood, were significant on bivariate analysis only. Toxocariasis is common in Lebanon. A large population-based survey is needed to confirm these results.


Subject(s)
Antibodies, Helminth/blood , Toxocara canis/immunology , Toxocariasis/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Blotting, Western , Cats , Dogs , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Lebanon/epidemiology , Male , Middle Aged , Odds Ratio , Pilot Projects , Risk Factors , Seroepidemiologic Studies , Sex Factors , Socioeconomic Factors , Toxocariasis/immunology
16.
Eur J Clin Microbiol Infect Dis ; 23(11): 836-40, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15558341

ABSTRACT

Described here is a case of Pseudallescheria boydii cranial osteomyelitis and subdural empyema following craniotomy, which was successfully treated with surgical debridement and voriconazole. Other reported cases of Pseudallescheria boydii osteomyelitis are reviewed. The reported case suggests that voriconazole may represent a new therapeutic option for this infection.


Subject(s)
Antifungal Agents/therapeutic use , Empyema, Subdural/drug therapy , Mycoses/drug therapy , Osteomyelitis/drug therapy , Pseudallescheria/isolation & purification , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Adult , Empyema, Subdural/microbiology , Female , Humans , Mycoses/microbiology , Osteomyelitis/microbiology , Pseudallescheria/drug effects , Voriconazole
17.
Scand J Infect Dis ; 36(6-7): 505-6, 2004.
Article in English | MEDLINE | ID: mdl-15307584

ABSTRACT

Acute appendicitis due to cytomegalovirus is exceedingly rare. It occurs mostly in individuals with the acquired immunodeficiency syndrome and has been reported once in an immunocompetent patient. This report describes a man who developed acute appendicitis following acute Epstein-Barr virus infection, and in whom cytomegalovirus was incriminated based on pathological examination.


Subject(s)
Appendicitis/virology , Cytomegalovirus Infections/complications , Epstein-Barr Virus Infections/complications , Immunocompetence , Acute Disease , Adult , Cytomegalovirus/pathogenicity , Humans , Male
18.
J Infect ; 45(3): 152-9, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12387770

ABSTRACT

OBJECTIVES: Infective endocarditis (IE) remains a disease associated with high morbidity and mortality. Many epidemiological studies have been reported worldwide; however, data from the Middle East is scarce. Most studies have recently shown a trend towards increasing incidence of Staphylococcus aureus endocarditis and decreasing prevalence of rheumatic heart disease as a predisposing condition. METHODS: We conducted a retrospective review of all recorded cases of IE in adult patients admitted between 1986 and 2001 to the American University of Beirut-Medical Centre. RESULTS: The total number of cases was 91. The mean age was 48 years. Fifty-nine percent of patients had a predisposing cardiac condition, rheumatic heart disease being the most common (33%). Blood cultures were positive in 77.5% of the cases: the most commonly isolated organisms were Streptococcus spp. (51%; of which 57% were viridans streptococci.) and Staphylococcus spp. (36%; of which 72% were S. aureus and 28% were coagulase-negative staphylococci). Transoesophageal echocardiography was performed in 36 patients (40%), of which 32 (89%) showed positive findings. When applying the revised Duke criteria, 82% of the patients were classified as definite and 16.5% as possible endocarditis. Surgery was performed in 32% of cases mostly for valvular regurgitation, followed by heart failure. The complication rate was 69% with congestive heart failure, drug-related toxicities, new valvular regurgitation and systemic embolisation being the most common. The in-hospital mortality rate was 18%. CONCLUSIONS: Unlike data reported from the United States and northern Europe, this study confirms that in Lebanon, a developing country, we continue to have a predominance of streptococci as aetiologic agents in IE, and rheumatic heart disease as the most common underlying heart condition. Application of the revised Duke criteria was useful in confirming the diagnosis of IE.


Subject(s)
Endocarditis, Bacterial/epidemiology , Streptococcal Infections/epidemiology , Academic Medical Centers/organization & administration , Adolescent , Adult , Aged , Aminoglycosides/pharmacology , Aminoglycosides/therapeutic use , Chronic Disease/classification , Chronic Disease/epidemiology , Echocardiography/methods , Endocarditis, Bacterial/etiology , Endocarditis, Bacterial/mortality , Epidemiologic Studies , Female , Heart Diseases/complications , Heart Diseases/mortality , Humans , Incidence , Lebanon/epidemiology , Male , Penicillins/pharmacology , Penicillins/therapeutic use , Streptococcal Infections/etiology , Streptococcus/classification , Streptococcus/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL
...